Conference Coverage

Impaired kidney function no problem for dabigatran reversal


 

REPORTING FROM ACC 18


In patients with severe renal dysfunction given idarucizumab, “be alert for a recurrent bleed,” which could require a second dose of idarucizumab, Dr. Eikelboom suggested.

SOURCE: Eikelboom JW et al. ACC 18, Abstract 1231M-11.

Pages

Recommended Reading

VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Internal Medicine
VIDEO: Case for rivaroxaban & aspirin for PAD gets stronger
MDedge Internal Medicine
VIDEO: PFO closure device 100% effective against future strokes
MDedge Internal Medicine
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
MDedge Internal Medicine
Protocol helped identify hospitalized children at risk for VTE
MDedge Internal Medicine
Few acutely ill hospitalized patients receive VTE prophylaxis
MDedge Internal Medicine
Apixaban prevails in study of 163,000 DOAC users
MDedge Internal Medicine
Clopidogrel flunks platelet reactivity control test in TAVI
MDedge Internal Medicine
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Internal Medicine
VTE risk after bariatric surgery should be assessed
MDedge Internal Medicine